Cardiac Implantable Electronic Device Induced Tricuspid Regurgitation: A Mini Review

Cover Page

Cite item

Full Text

Abstract

The continuing application of cardiac implantable electronic devices (CIED) has led to an increasing concern regarding disturbances in the tricuspid valve (TV). The most prevalent TV issue related to lead implantation is tricuspid regurgitation. CIED-induced tricuspid regurgitation is associated with emerging or worsening preexisting heart failure and increased mortality rate. Because discontinuing the implantation of these instruments is not feasible, further knowledge of their mechanical problems may lead to advancements. This review addresses the available data regarding CIED-induced tricuspid regurgitation, elucidating its plausible pathomechanisms, diagnostic methods, and prospective treatments.

About the authors

Rana Zhafira Amanda

Airan Raya Hospital

Email: ranazhaf@gmail.com
ORCID iD: 0000-0002-8686-1834

MD; General Practitioner Airan Raya Hospital

Indonesia, South Lampung

Sidhi Laksono Purwowiyoto

Faculty Of Medicine, Universitas Muhammadiyah Prof Dr Hamka

Author for correspondence.
Email: sidhilaksono@uhamka.ac.id
ORCID iD: 0000-0002-2959-8937

MD, CPHM, Lecturer; Department of Cardiology, Faculty of Medicine, Prof Dr Hamka Muhammadiyah University

Indonesia, Tangerang

References

  1. Gelves-Meza J, Lang RM, Valderrama-Achury MD, et al. Tricuspid regurgitation related to cardiac implantable electronic devices: an integrative review. J Am Soc Echocardiogr. 2022;35(11):1107–1122. doi: 10.1016/j.echo.2022.08.004
  2. Offen S, Strange G, Playford D, et al. Prevalence and prognostic impact of tricuspid regurgitation in patients with cardiac implantable electronic devices: From the national echocardiography database of Australia. Int J Cardiol. 2023;370:338–344. doi: 10.1016/j.ijcard.2022.10.160
  3. Husain A, Raja FT, Fatallah A, et al. Tricuspid stenosis: An emerging disease in cardiac implantable electronic devices era. Case report and literature review. J Cardiol Cases. 2017;15(6):190–193. doi: 10.1016/j.jccase.2017.02.003
  4. Addetia K, Harb SC, Hahn RT, et al. Cardiac implantable electronic device lead-induced tricuspid regurgitation. JACC Cardiovasc Imaging. 2019;12(4):622–636. doi: 10.1016/j.jcmg.2018.09.028
  5. Nakajima H, Seo Y, Ishizu T, et al. Features of lead-induced tricuspid regurgitation in patients with heart failure events after cardiac implantation of electronic devices – A three-dimensional echocardiographic study. Circ J. 2020;84(12):2302–2311. doi: 10.1253/circj.CJ-20-0620
  6. Zhang XX, Wei M, Xiang R, et al. Incidence, risk factors, and prognosis of tricuspid regurgitation after cardiac implantable electronic device implantation: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2022;36(6):1741–1755. doi: 10.1053/j.jvca.2021.06.025
  7. Seo Y, Nakajima H, Ishizu T, et al. Comparison of outcomes in patients with heart failure with versus without lead-induced tricuspid regurgitation after cardiac implantable electronic devices implantations. Am J Cardiol. 2020;130:85–93. doi: 10.1016/j.amjcard.2020.05.039
  8. Andreas M, Burri H, Praz F, et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J. 2024;45(5): 346–365. doi: 10.1093/eurheartj/ehad783
  9. Chodór-Rozwadowska KE, Sawicka M, Morawski S, et al. Lead-related tricuspid regurgitation and ventricle dysfunction: Current management and future perspectives. Adv Clin Exp Med. 2023;32(9):1049–1061. doi: 10.17219/acem/159531
  10. Carino D, Sala A, Zancanaro E, et al. Surgical treatment of tricuspid valve regurgitation in patients with cardiac implantable electronic devices: long-term results. Eur J Cardiothoracic Surg. 2022;62(3):ezac239. doi: 10.1093/ejcts/ezac239
  11. Stankovic I, Voigt JU, Burri H, et al. Imaging in patients with cardiovascular implantable electronic devices: part 2—imaging after device implantation. A clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI) and the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J Cardiovasc Imaging. 2023.25(1).e33–e54. doi: 10.1093/ehjci/jead273
  12. Javed N, Iqbal R, Malik J, et al. Tricuspid insufficiency after cardiac-implantable electronic device placement. J Community Hosp Intern Med Perspect. 2021;11(6):793–798. doi: 10.1080/20009666.2021.1967569
  13. Alnaimat S, Doyle M, Krishnan K, Biederman RWW. Worsening tricuspid regurgitation associated with permanent pacemaker and implantable cardioverter-defibrillator implantation: A systematic review and meta-analysis of more than 66,000 subjects. Heart Rhythm. 2023.20(11):1491–1501. doi: 10.1016/j.hrthm.2023.07.064
  14. Papageorgiou N, Falconer D, Wyeth N, et al. Effect of tricuspid regurgitation and right ventricular dysfunction on long-term mortality in patients undergoing cardiac devices implantation: >10-year follow-up study. Int J Cardiol. 2020;319:52–56. doi: 10.1016/j.ijcard.2020.05.062
  15. Kanawati J, Ng ACC, Khan H, et al. Long-term follow-up of mortality and heart failure hospitalisation in patients with intracardiac device-related tricuspid regurgitation. Heart Lung Circ. 2021;30(5):692–697. doi: 10.1016/j.hlc.2020.08.028
  16. Safiriyu I, Mehta A, Adefuye M, et al. Incidence and prognostic implications of cardiac-implantable device-associated tricuspid regurgitation: a meta-analysis and meta-regression analysis. Am J Cardiol. 2023;209:203–211. doi: 10.1016/j.amjcard.2023.09.064
  17. Van De Heyning CM, Elbarasi E, Masiero S, et al. Prospective study of tricuspid regurgitation associated with permanent leads after cardiac rhythm device implantation. Can J Cardiol. 2019;35(4): 389–395. doi: 10.1016/j.cjca.2018.11.014
  18. Arabi P, Özer N, Ateş AH, et al. Effects of pacemaker and implantable cardioverter defibrillator electrodes on tricuspid regurgitation and right sided heart functions. Cardiol J. 2015;22(6):637–644. doi: 10.5603/CJ.a2015.0060
  19. Guigui S, Zedan A, LaPietra A, et al. Cardiovascular implantable electronic device-related tricuspid regurgitation: A multidisciplinary team approach. J Thorac Dis. 2020;12(5):2986–2989. doi: 10.21037/jtd.2020.01.64
  20. Ehra A, Task A, Members F, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology ( ESC ) With the special contribution of the European Heart Rhythm. 2021;1–94. doi: https://academic.oup.com/eurheartj/article/42/35/3427/6358547?login=false
  21. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Rev Esp Cardiol (Engl Ed). 2022;75(6):524. doi: 10.1016/j.rec.2022.05.006
  22. Lurz J, Rommel KP, Unterhuber M, et al. Safety and efficacy of transcatheter edge-to-edge repair of the tricuspid valve in patients with cardiac implantable electronic device leads. JACC Cardiovasc Interv. 2019;12(20):2114–2116. doi: 10.1016/j.jcin.2019.05.034

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Diagram ilustrating study selection process

Download (311KB)
Indexing metadata

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).